In this article the third Key Point was incorrectly given as: 'Data for children and subjects aged <65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.' but should have been: 'Data for children and subjects aged >65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.'. The original article has been corrected.
Correction to: Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan (Drugs, (2024), 84, 6, (661-684), 10.1007/s40265-024-02037-0) / Lombardi, Carlo; Comberiati, Pasquale; Ridolo, Erminia; Cottini, Marcello; Yacoub, Mona Rita; Casagrande, Silvia; Ricco, Matteo; Bottazzoli, Marco; Berti, Alvise. - In: DRUGS. - ISSN 0012-6667. - 85:4(2025), pp. 599-599. [10.1007/s40265-025-02149-1]
Correction to: Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan (Drugs, (2024), 84, 6, (661-684), 10.1007/s40265-024-02037-0)
Berti, Alvise
Ultimo
2025-01-01
Abstract
In this article the third Key Point was incorrectly given as: 'Data for children and subjects aged <65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.' but should have been: 'Data for children and subjects aged >65 years are however scarce, resulting in a lack of evidence for the use of anti-interleukin-5 agents in these specific patient populations.'. The original article has been corrected.| File | Dimensione | Formato | |
|---|---|---|---|
|
40265_2025_Article_2149 alvise.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
390 kB
Formato
Adobe PDF
|
390 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
